ASX ANNOUNCEMENT

16 November 2026

Non-Executive Director Resignation

Saluda Medical, Inc. (ASX:SLD, "Saluda" or the "Company") today announced that Quentin Blackford has decided to step down as Non-Executive Director effective as of the date of the Company's Annual General Meeting of Stockholders ("AGM"), which is 18 November 2026, to focus on his other business and professional responsibilities.

Mr Blackford has served as a member of the Board since the Company's IPO in 2025, including as Chairman of the Compensation Committee and as a member of the Audit & Risk Committee.

Doug Godshall, Chairman of the Saluda Medical Board, stated "On behalf of management and the entire Board of Directors, I would like to thank Quentin for his dedication, guidance and contribution to the Company during his tenure. His wise counsel and strategic guidance on a broad array of operational and financial matters have been highly valued during what has been a transformative period for Saluda. We appreciate his leadership and wish him all the best in his future endeavours."

This announcement has been authorised for release by Saluda Medical's Disclosure Committee.

For more information, please contact:

Investors
James Erickson
Chief Financial Officer
investors@saludamedical.com

Sam Wells
NWR Communications
+61 (0) 427 630 152
sam@nwrcommunications.com.au

Media
Matt Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About Saluda Medical

Saluda Medical is a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel neuromodulation platform. The Company's closed-loop, dose-control platform senses and measures neural responses to stimulation and automatically adjusts therapy based on real-time neurophysiological feedback. The Company's first product, the Evoke® System, is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain, and is designed to treat chronic neuropathic pain by providing spinal cord stimulation (SCS) therapy that senses and measures neural activation to optimize therapy and reduce patient and clinician burden. 12-month results from the EVOKE study, the first and only prospective, multi-center, parallel-arm, double blind, randomized controlled pivotal study with a voluntary crossover arm in SCS, that demonstrated clinically superior pain relief to open-loop therapy, were published in The Lancet Neurology, 24-month results were published in JAMA Neurology, and 36-month data, that demonstrated sustained pain relief, were published in Regional Anesthesia and Pain Medicine.

To learn more, including risks and important safety information, visit www.saludamedical.com/us/safety/.

Foreign Ownership Restriction

Saluda's CHESS Depositary Interests (CDIs) are issued in reliance on Regulation S under the U.S. Securities Act of 1933, as amended (the U.S. Securities Act), and a no-action letter issued by the staff of the U.S. Securities and Exchange Commission. Accordingly, the Company's CDIs have not been, and will not be, registered under the U.S. Securities Act (except pursuant to an effective registration statement) or the securities laws of any state or other jurisdiction in the United States. The holders of Saluda's CDIs may not offer, sell, pledge, or otherwise transfer the CDIs into the United States or to, or for the account or benefit of, a "U.S. Person" (as defined in Rule 902(k) of Regulation S under the U.S. Securities Act) for a period of at least 12 months from the allotment date under the IPO, unless the resale of the CDIs is registered under the U.S. Securities Act or an exemption from registration is available.